BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at HC Wainwright from $90.00 to $100.00. They now have a "buy" rating on the stock.
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia [Yahoo! Finance]
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $81.00 to $83.00. They now have an "outperform" rating on the stock.